Otsuka v. Alkem: Tolvaptan Patent Dispute Ends in Stipulated Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Otsuka Pharmaceutical Co., Ltd. v. Alkem Laboratories Ltd. |
| Case Number | 1:25-cv-00318 |
| Court | U.S. District Court for the District of Delaware |
| Duration | Mar 2025 – Jan 2026 315 days |
| Outcome | Dismissal – Without Prejudice |
| Patents at Issue | |
| Accused Products | Alkem’s proposed generic tolvaptan tablets (15, 30, 45, 60, and 90 mg dosage forms) |
Case Overview
The Parties
⚖️ Plaintiff
Tokyo-headquartered global pharmaceutical company with a robust U.S. commercial presence. JYNARQUE® (tolvaptan) represents a significant revenue asset for the company.
🛡️ Defendant
Mumbai-based generic pharmaceutical manufacturer with active U.S. market operations, seeking to enter the ADPKD treatment market with generic tolvaptan.
The Patents at Issue
This landmark case involved three U.S. patents asserted by Otsuka, forming a layered exclusivity shield around JYNARQUE® (tolvaptan):
- • US10905694B2 — Covers pharmaceutical formulations or methods related to tolvaptan therapy.
- • US8273735B2 — An earlier foundational patent in the tolvaptan family, likely covering compound or composition claims.
- • US8501730B2 — A continuation or related application extending protection over tolvaptan-related subject matter.
Developing a similar pharmaceutical product?
Check if your drug formulation or method might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On January 22, 2026, the parties filed a **Rule 41(a)(1)(A)(ii) Stipulated Dismissal**, jointly agreeing to dismiss all claims, counterclaims, and affirmative defenses **without prejudice** and **without costs or attorneys’ fees** to either party. The court retained jurisdiction to enforce the stipulated dismissal and any related agreements resolving the matter.
No damages were adjudicated, and no injunctive relief was formally granted or denied by the court.
Verdict Cause Analysis
The case was initiated as a straightforward **pharmaceutical patent infringement action**—the standard Hatch-Waxman mechanism triggered when a brand manufacturer receives a Paragraph IV certification from a generic applicant challenging patent validity or asserting non-infringement. Otsuka’s filing within the statutory 30-month window would have automatically triggered an FDA approval stay on Alkem’s ANDA during litigation.
The dismissal without prejudice is legally significant: it preserves both parties’ rights. Otsuka retains the ability to re-file infringement claims if circumstances change, while Alkem retains all invalidity and non-infringement defenses. This structure strongly suggests the parties reached a **confidential license or settlement agreement**—a common Hatch-Waxman resolution where the generic manufacturer receives a negotiated entry date in exchange for dropping validity challenges.
Drafting pharmaceutical patents?
Learn from this case. Use AI to draft stronger claims that can withstand ANDA litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for tolvaptan and ADPKD treatments.
- View the full multi-patent family for tolvaptan
- See which companies are most active in ADPKD IP
- Understand claim construction patterns for pharmaceutical formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Tolvaptan compounds and formulations
3 Asserted Patents
Protecting JYNARQUE® (tolvaptan)
Patent Landscape Insights
Available for strategic development
✅ Key Takeaways
For Patent Attorneys & Litigators
Rule 41(a)(1)(A)(ii) stipulated dismissals with court-retained jurisdiction in ANDA cases are strong indicators of confidential licensing agreements—analyze them as settlements, not litigation failures.
Search related case law →Three-patent assertion portfolios across US10905694B2, US8273735B2, and US8501730B2 created multi-layered infringement risk for Alkem, likely accelerating resolution.
Explore precedents →Delaware District Court, under Chief Judge Bibas, remains a preferred and efficient ANDA venue.
View Delaware District Court filings →For IP Professionals
Brand pharmaceutical companies should continuously expand patent family depth around blockbuster assets to maximize Hatch-Waxman leverage.
Analyze patent portfolio strategies →Monitor Orange Book listings for JYNARQUE® for post-settlement patent additions or expirations affecting market exclusivity timelines.
Check FDA Orange Book →For R&D Leaders
FTO assessments in the tolvaptan space must encompass the full multi-patent family, not solely lead composition patents.
Start FTO analysis for my product →Competitive ADPKD drug development timelines may be influenced by Alkem’s negotiated market entry date if a settlement was reached.
Explore competitive intelligence →Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in the pharma sector.